scPharmaceuticals Inc. Quarterly Operating Income (Loss) in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
scPharmaceuticals Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2017 to Q3 2024.
  • scPharmaceuticals Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$18.1M, a 22.3% decline year-over-year.
  • scPharmaceuticals Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$63.7M, a 28.3% decline year-over-year.
  • scPharmaceuticals Inc. annual Operating Income (Loss) for 2023 was -$55.4M, a 53.2% decline from 2022.
  • scPharmaceuticals Inc. annual Operating Income (Loss) for 2022 was -$36.2M, a 40% decline from 2021.
  • scPharmaceuticals Inc. annual Operating Income (Loss) for 2021 was -$25.8M, a 13.7% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$63.7M -$18.1M -$3.31M -22.3% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$60.4M -$14.4M -$685K -4.98% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$59.7M -$15.9M -$4.3M -37.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$55.4M -$15.3M -$5.76M -60.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-13
Q3 2023 -$49.6M -$14.8M -$4.84M -48.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$44.8M -$13.7M -$4.33M -45.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$40.5M -$11.6M -$4.31M -59.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$36.2M -$9.5M -$2.78M -41.4% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-13
Q3 2022 -$33.4M -$10M -$4.09M -69.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$29.3M -$9.42M -$2.97M -45.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$26.3M -$7.24M -$499K -7.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 -$25.8M -$6.72M +$449K +6.26% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-22
Q3 2021 -$26.3M -$5.91M +$2.53M +30% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$28.8M -$6.46M +$1.22M +15.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$30M -$6.74M -$92K -1.38% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$29.9M -$7.17M +$3.26M +31.3% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-22
Q3 2020 -$33.2M -$8.44M -$2.15M -34.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$31M -$7.68M -$341K -4.65% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 -$30.7M -$6.65M +$2.2M +24.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
Q4 2019 -$32.9M -$10.4M -$5.21M -99.8% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-23
Q3 2019 -$27.7M -$6.29M -$448K -7.67% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 -$27.2M -$7.34M +$2.57M +25.9% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 -$29.8M -$8.85M -$148K -1.7% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q4 2018 -$29.7M -$5.22M +$1.49M +22.1% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-24
Q3 2018 -$31.2M -$5.84M -$591K -11.3% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$30.6M -$9.9M -$3.39M -51.9% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 -$27.2M -$8.7M -$3.74M -75.4% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q4 2017 -$23.4M -$6.71M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-21
Q3 2017 -$5.25M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 -$6.52M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
Q1 2017 -$4.96M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.